Epigenomics AG (FRA:ECX) Current Deferred Revenue: €0.00 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:ECX Epigenomics AG FRA:ECX
16 GF Score
Price €0.94
GF Value €0.09
Valuation Significantly Overvalued
! 3 Warning Signs
View Full Analysis

What is Epigenomics AG Current Deferred Revenue?

Epigenomics AG FRA:ECX 16 Current Deferred Revenue is €0.00 Mil as of Dec. 2025. GuruFocus rates FRA:ECX with a GF Score™ of 16/100 and a GF Value™ of €0.09 (Significantly Overvalued). The stock has 3 warning signs investors should review.

Current Deferred Revenue represents collections of cash or other assets related to revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP. It can be either current or non-current item. Also called unearned revenue.

Epigenomics AG's current deferred revenue for the quarter that ended in Dec. 2025 was €0.00 Mil.

Epigenomics AG Current Deferred Revenue Related Terms

Epigenomics AG Current Deferred Revenue Historical Data

* Premium members only.

The historical data trend for Epigenomics AG's Current Deferred Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Epigenomics AG Current Deferred Revenue Chart

Epigenomics AG Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Current Deferred Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Epigenomics AG Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Current Deferred Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
FRA:ECX
16GF Score
Epigenomics AG FRA:ECX
Current Deferred Revenue is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Current Deferred Revenue of €0.00 Mil mean?
Epigenomics AG (FRA:ECX) has a Current Deferred Revenue of €0.00 Mil as of Dec. 2025. Current Deferred Revenue records the total amount of cash received for unfinished services. View historical data on Epigenomics AG and its competitors.
Is Epigenomics AG's Current Deferred Revenue too high?
Epigenomics AG's current Current Deferred Revenue is €0.00 Mil. Overall, Epigenomics AG has a GF Score™ of 16/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Epigenomics AG's Current Deferred Revenue compare to TMO and DHR?
Epigenomics AG's Current Deferred Revenue of €0.00 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Deferred Revenue for a Medical Diagnostics & Research company?
A good Current Deferred Revenue depends on the Medical Diagnostics & Research industry context. However, Current Deferred Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Deferred Revenue mean?
A high Current Deferred Revenue can signal that a stock is expensive relative to its fundamentals. Current Deferred Revenue records the total amount of cash received for unfinished services. View historical data on Epigenomics AG and its competitors. Epigenomics AG's current Current Deferred Revenue is €0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Epigenomics AG stock overvalued right now?
Based on GuruFocus' analysis, Epigenomics AG (FRA:ECX) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.09, compared to a current price of €0.94 — trading 944.4% above its estimated fair value. The current Current Deferred Revenue is €0.00 Mil. Epigenomics AG's overall GF Score™ is 16/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Deferred Revenue calculated?
Current Deferred Revenue is calculated from a company's financial statements. For Epigenomics AG (FRA:ECX), the current Current Deferred Revenue is €0.00 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Epigenomics AG (FRA:ECX) Overvalued in 2026?

Based on GuruFocus' analysis, Epigenomics AG stock appears to be overvalued. The current stock price of €0.94 is trading 944.4% above its estimated GF Value™ of €0.09. GuruFocus considers Epigenomics AG to be Significantly Overvalued.

Key valuation signals for FRA:ECX:

  • Current Deferred Revenue: €0.00 Mil
  • GF Value™: €0.09 vs. price of €0.94 (944.4% above fair value)
  • GF Score™: 16/100 with 3 warning signs

No single metric tells the full story. See the FRA:ECX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Epigenomics AG Business Description

Other Exchanges ECX:Germany
Address Ziegelhauser Landstrabe 3, Heidelberg, BW, DEU, 69120
Epigenomics AG is a molecular diagnostics company, that focuses on developing and commercializing in vitro diagnostic liquid biopsy tests for the screening, early detection, and diagnosis of cancer. The company develops and markets procedures and devices for the production in quantity of particular epigenetic parameters such as DNA methylation patterns as well as the information technology bases necessary for their procurement and evaluation. It is engaged in the development of novel molecular diagnostic products for cancer. The company products include Epi proColon, Epi BiSKit, HCCBloodTest, and Epi proLung. The company operates in Europe, Asia, and North America, majority of its revenue derives from Asia.
16GF Score

Get the complete analysis for FRA:ECX

Current Deferred Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.94
Price
€0.09
GF Value